Screener
Immunome IMNM Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -64%+17.2pp | -50.1%+19.1pp | -52.1%+143pp | -93%+183pp | -81.2%+118pp | |
| Return on invested capital | -122.5%+81.0pp | -746.6%-135pp | —— | —— | -203.4%— | |
| Efficiency | ||||||
| Asset turnover | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Liquidity | ||||||
| Current ratio | 15.1×+3.0× | 21.7×+11.2× | 14.7×+10.6× | 8.9×+2.7× | 12.1×+5.0× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $4.64+49.8% | $5.20+34.5% | $7.26+135% | $3.00-15.9% | $3.09-26.9% | |
| Valuation | ||||||
| Market capitalization | $2.37B+138% | $2.47B+323% | $2.37B+258% | $1.02B+16.1% | $776.15M+7.0% | |
| Price / book | 4.5×+0.7× | 4.2×+2.3× | 3.7×+0.1× | 3.9×-0.2× | 2.9×0.0× |
FAQ
- Where do Immunome's ratios come from?
- Every ratio is computed from Immunome's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.